Steven T. Sobieski Joins Insulet Corporation's Board Of Directors

BEDFORD, Mass., Feb. 20 /PRNewswire/ -- Steven T. Sobieski, Vice President, Finance & Administration and Chief Financial Officer of LifeCell Corporation, has joined the Board of Directors of Insulet Corporation. A Certified Public Accountant with more than 16 years of experience in medical technology financial management, Mr. Sobieski will chair Insulet's Audit Committee. Insulet develops, manufactures and markets the OmniPod(R) Insulin Management System, an innovative product for the treatment of diabetes that brings together safe, reliable, continuous subcutaneous insulin infusion and blood glucose monitoring in an easy-to-use, discreet two-part system.

In announcing the appointment, Duane DeSisto, Insulet President & CEO, said, "Steve brings a tremendous amount of experience in medical technology financial management to our Board. His experience and guidance will be invaluable to us as we expand our market reach for the OmniPod System."

"It is a tremendous opportunity to be involved with such an innovative company and product at the Board level," Sobieski said. "I look forward to helping Insulet expand the use of continuous subcutaneous insulin infusion therapy with the OmniPod System and achieve its business objectives."

Mr. Sobieski has held a variety of roles in financial management in the public accounting and medical technology fields. He joined LifeCell in June 2000 as Vice President, Finance & Administration and Chief Financial Officer. LifeCell develops and markets products made from human tissue for use in reconstructive, orthopedic and urogynecologic surgical procedures.

Prior to joining LifeCell, Mr. Sobieski was Vice President, Finance at Osteotech, Inc., a publicly traded NASDAQ company focused on developing and marketing human tissue based products for orthopedic applications. He served in various positions at Osteotech from 1991 to 2000. From 1981 through 1991, he served in positions of increasing responsibility with Coopers & Lybrand. Mr. Sobieski received his Bachelor of Science degree in Business Administration from Monmouth University, and his Master of Business Administration degree, with a concentration in accounting, from Rutgers University.

Mr. Sobieski joins these executives on Insulet Corporation's Board of Directors:

- Alison de Bord, Director, Alta Partners - Duane DeSisto, President & Chief Executive Officer, Insulet Corporation - Gary Eichhorn, Former General Manager, Hewlett Packard Medical Products Group - Ross A. Jaffe, M.D., Managing Director, Versant Ventures - Charles T. Liamos, Executive in Residence, MedVenture Associates - Gordie Nye, General Partner, Prism Venture Partners - Jonathan T. Silverstein, JD, General Partner, OrbiMed About Insulet Corporation

Founded in 2000, Insulet Corporation is a privately-held medical device company located in Bedford, Massachusetts. The company seeks to improve the lives of people with diabetes and expand the use of continuous subcutaneous insulin infusion (CSII) therapy through innovative technology and feedback from people with diabetes and healthcare professionals. Insulet Corporation develops, manufactures and markets the OmniPod Insulin Management System, an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes.

For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com

CONTACT: Joanne Stanway, +1-978-273-1473, or jstanway@ryanwellnitz.com, orBarbara Wellnitz, +1-508-698-3374, or bwellnitz@ryanwellnitz.com, both ofRyan Wellnitz & Associates

Web site: http://www.insulet.com/